No we shouldn’t be at trading a .30, the current projected numbers and math doesn’t support it, (however we should expect these to improve) Right now. .30 is the break even point. No one buys to break even. Where we should be trading is at .10 to .15. There has been some delays in this because of the recent activity shows retail is trying to cash in on the small pop from the pr instead of letting it run.
Do you think this company doesn't get the traditional valuation because they never take the traditional steps? In almost everything they do they seem to go alternate routes. Clinicals in Bulgaria, and Africa instead of FDA. Everyone blames corruption for this company not thriving in the past, but they also seem to avoid the practices that are trusted by investors in the Bio field. It's just a possibility that their routes are a double edge sword that both can benefit them in the long run, but causes pain in the short term.
News 
Market Data 
Discover 
